GPX4-IN-20

GPX4-IN-20 (compound W25) (2.5-10 μM; 24-72 h) shows cytotoxic activity on HCT-116 cells^[1].
GPX4-IN-20 (2.5-10 μM; 24 hours; HCT-116 cells) inhibits GPX4 protein expression and activity, promoting ubiquitination-dependent proteasomal degradation. GPX4-IN-20 has no significant effect on other key regulatory factors of ferroptosis, such as ferroptosis suppressor protein 1 (FSP1), ferritin heavy chain 1 (FTH1), nuclear receptor coactivator 4 (NCOA4), and solute carrier family 7 member 11 (SLC7A11)^[1].
GPX4-IN-20 (2.5-10 μM; 24 hours; HCT-116 cells) does not affect GPX4 mRNA levels^[1].
GPX4-IN-20 (0, 2.5, 5, 10 μM; 6 h) inhibits the clone formation of HCT-116 cells in a dose-dependent manner^[1].
GPX4-IN-20 (24 h) inhibits the cell growth of HT-29 with an IC₅₀ of 4.60 μM^[1].
GPX4-IN-20 (0, 2.5, 5, 10 μM; 6, 12, 24 hours; HCT-116 cells) significantly increases the lipid ROS levels in HCT-116 cells with a dose- and time-dependent manner. GPX4-IN-20 significantly decreases GPX4 levels. After treatment with GPX4-IN-20, intracellular MDA content is increased in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.